Mouse models characterize GNAO1 encephalopathy as a neurodevelopmental disorder leading to motor anomalies: from a severe G203R to a milder C215Y mutation.
Dominant
Encephalopathy
Epilepsy
GNAO1
Gαo
Hyperkinetic movement disorder
Mouse model
Neurodevelopmental
Neuronal precursors
Journal
Acta neuropathologica communications
ISSN: 2051-5960
Titre abrégé: Acta Neuropathol Commun
Pays: England
ID NLM: 101610673
Informations de publication
Date de publication:
28 01 2022
28 01 2022
Historique:
received:
17
11
2021
accepted:
08
01
2022
entrez:
29
1
2022
pubmed:
30
1
2022
medline:
24
3
2022
Statut:
epublish
Résumé
GNAO1 encephalopathy characterized by a wide spectrum of neurological deficiencies in pediatric patients originates from de novo heterozygous mutations in the gene encoding Gαo, the major neuronal G protein. Efficient treatments and even the proper understanding of the underlying etiology are currently lacking for this dominant disease. Adequate animal models of GNAO1 encephalopathy are urgently needed. Here we describe establishment and characterization of mouse models of the disease based on two point mutations in GNAO1 with different clinical manifestations. One of them is G203R leading to the early-onset epileptic seizures, motor dysfunction, developmental delay and intellectual disability. The other is C215Y producing much milder clinical outcomes, mostly-late-onset hyperkinetic movement disorder. The resultant mouse models show distinct phenotypes: severe neonatal lethality in GNAO1[G203R]/ + mice vs. normal vitality in GNAO1[C215Y]/ + . The latter model further revealed strong hyperactivity and hyperlocomotion in a panel of behavioral assays, without signs of epilepsy, recapitulating the patients' manifestations. Importantly, despite these differences the two models similarly revealed prenatal brain developmental anomalies, such as enlarged lateral ventricles and decreased numbers of neuronal precursor cells in the cortex. Thus, our work unveils GNAO1 encephalopathy as to a large extent neurodevelopmental malady. We expect that this understanding and the tools we established will be instrumental for future therapeutic developments.
Identifiants
pubmed: 35090564
doi: 10.1186/s40478-022-01312-z
pii: 10.1186/s40478-022-01312-z
pmc: PMC8796625
doi:
Substances chimiques
GNAO1 protein, mouse
EC 3.6.5.1
GTP-Binding Protein alpha Subunits, Gi-Go
EC 3.6.5.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
9Informations de copyright
© 2022. The Author(s).
Références
Neurol Genet. 2017 Mar 21;3(2):e143
pubmed: 28357411
Nat Rev Neurosci. 2007 Jun;8(6):427-37
pubmed: 17514196
Hum Mol Genet. 2021 Sep 11;:
pubmed: 34508586
Neuropsychopharmacology. 2020 Nov;45(12):2020-2029
pubmed: 32585679
Mamm Genome. 2014 Jun;25(5-6):202-10
pubmed: 24700286
Mol Ther Nucleic Acids. 2015 Nov 17;4:e264
pubmed: 26575098
Curr Opin Neurobiol. 2008 Feb;18(1):28-35
pubmed: 18508260
Eur J Hum Genet. 2016 Jan;24(1):129-34
pubmed: 25966631
Neuropediatrics. 2017 Oct;48(5):371-377
pubmed: 28628939
J Neurol Sci. 2018 Aug 15;391:31-39
pubmed: 30103967
Cell Biol Toxicol. 2020 Feb;36(1):5-9
pubmed: 31734746
J Neurosci. 2018 Apr 11;38(15):3776-3791
pubmed: 29555850
Cells. 2021 Oct 14;10(10):
pubmed: 34685729
Neuron. 2015 Dec 16;88(6):1121-1135
pubmed: 26687221
J Vis Exp. 2018 Jun 12;(136):
pubmed: 29985308
Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3269-74
pubmed: 9501252
J Neurosci. 2009 Oct 28;29(43):13589-602
pubmed: 19864571
Front Neurol. 2021 May 28;12:662162
pubmed: 34122306
Epileptic Disord. 2017 Mar 1;19(1):67-75
pubmed: 28202424
Biotechniques. 2000 Jul;29(1):52, 54
pubmed: 10907076
Pediatr Neurol. 2016 Jun;59:81-4
pubmed: 27068059
eNeuro. 2020 Apr 7;7(2):
pubmed: 32144144
Parkinsonism Relat Disord. 2020 May;74:50-56
pubmed: 32334381
Neuron. 1995 Jul;15(1):63-78
pubmed: 7619531
Am J Hum Genet. 2013 Sep 5;93(3):496-505
pubmed: 23993195
Curr Protoc Neurosci. 2012;Chapter 9:Unit9.37
pubmed: 23042503
Cell Rep. 2021 Feb 2;34(5):108718
pubmed: 33535037
Res Commun Chem Pathol Pharmacol. 1985 Dec;50(3):435-41
pubmed: 3878557
Nat Methods. 2021 Jan;18(1):100-106
pubmed: 33318659
Hum Mol Genet. 2021 Oct 08;:
pubmed: 34622282
J Pharmacol Exp Ther. 2020 Apr;373(1):24-33
pubmed: 31907305
Orphanet J Rare Dis. 2016 Apr 12;11:38
pubmed: 27072799
Epilepsia. 2019 Mar;60(3):406-418
pubmed: 30682224
Neurobiol Dis. 2011 Jun;42(3):231-41
pubmed: 21238589
Mov Disord. 2019 Oct;34(10):1516-1527
pubmed: 31216378
J Neural Transm (Vienna). 2019 Jun;126(6):739-757
pubmed: 31076915
Parkinsonism Relat Disord. 2019 Apr;61:19-25
pubmed: 30642806
Nat Neurosci. 2020 Nov;23(11):1433-1443
pubmed: 32958923
Pediatr Neurol. 2021 Aug;121:28-32
pubmed: 34139551
Mol Brain. 2019 Jun 20;12(1):57
pubmed: 31221179
eNeuro. 2019 Feb 12;6(1):
pubmed: 30783615